3-硝基-4-羟基苯甲酸甲酯 | 99-42-3

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-硝基-4-羟基苯甲酸甲酯
• 中文别名: 4-羟基-3-硝基苯甲酸甲酯
• 英文名称: methyl (4-hydroxy-3-nitro)benzoate
• 英文别名: 4-hydroxy-3-nitrobenzoic acid methyl ester；methyl 3-nitro-4-hydroxybenzoate；3-nitro-4-hydroxy-benzoic acid methyl ester；Methyl 4-hydroxy-3-nitrobenzoate
• CAS: 99-42-3
• 化学式: C₈H₇NO₅
• mdl: MFCD00014695
• 分子量: 197.147
• InChiKey: GNCWCTBHZCBXGL-UHFFFAOYSA-N

物化性质

• 熔点：
  74-76°C
• 沸点：
  346.25°C (rough estimate)
• 密度：
  1.2569 (rough estimate)
• 稳定性/保质期：
  避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• TSCA：
  Yes
• 安全说明：
  S26,S36/37/39
• 海关编码：
  2918290000
• 危险类别码：
  R36/37/38
• RTECS号：
  DH2528400
• 危险性防范说明：
  P261,P280,P305+P351+P338,P304+P340,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  储存于阴凉、干燥、通风的专用爆炸品库房中。远离火种、热源，并与氧化剂分开存放，切忌混储。使用防爆型照明和通风设施，并禁止使用可能产生火花的机械设备和工具。储区应备有合适的材料以收容泄漏物。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Methyl 4-hydroxy-3-nitrobenzoate
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Methyl 4-hydroxy-3-nitrobenzoate
Ingredient name:
CAS number: 99-42-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7NO5
Molecular weight: 197.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

硝基取代的芳香族化合物，如3-硝基-4-羟基苯甲酸甲酯，是一种非常重要且广泛应用的中间体。它在医疗、农药、染料和炸药等多个领域都有着重要的应用价值。

反应信息

• 作为反应物：
  描述：

  3-硝基-4-羟基苯甲酸甲酯 在 palladium on activated charcoal ammonium hydroxide 、 氢气 作用下， 以 甲醇 为溶剂， 50.0~60.0 ℃ 、310.26 kPa 条件下， 反应 51.0h， 生成 3-氨基-4-羟基-苯甲酰胺
  参考文献：
  名称：

  Nonpeptide Inhibitors of Measles Virus Entry

  摘要：

  Measles virus (MV) is one of the most infectious pathogens known. Despite the existence of a vaccine, over 500 000 deaths/year result from MV or associated complications. Anti-measles compounds could conceivably reverse these statistics. Previously, we described a homology model of the MV fusion protein trimer and a putative binding site near the head-neck region. The resulting model permitted the identification of two nonpeptidic entry inhibitors. Here, we present the design, synthesis, and bioevaluation of several series of fusion inhibitors and describe their structure-activity relationships (SAR). Five simply substituted anilides show low-mu M blockade of the MV, one of which (AS-48) exhibits IC50 0.6-3.0 mu M across a panel of wild-type MV strains found in the field. Molecular field topology analysis (MFTA), a 2D QSAR approach based on local molecular properties (atomic charges, hydrogen-bonding capacity and local lipophilicity), applied to the anilide series suggests structural modifications to improve potency.

  DOI：

  10.1021/jm0602559
• 作为产物：
  描述：

  对羟基苯甲酸甲酯 在 silica supported Al(NO₃)3*9H₂O 作用下， 以 丙酮 为溶剂， 反应 0.75h， 以98%的产率得到3-硝基-4-羟基苯甲酸甲酯
  参考文献：
  名称：

  硝酸铝在二氧化硅上硝化体系对苯酚和苯醚的区域选择性硝化

  摘要：

  发现二氧化硅负载的硝酸铝（Al（NO3）3·9H2O）是用于苯酚和苯基醚硝化的极好试剂。该方法在室温下对大多数实施例有效地进行，以高的区域选择性以中等至良好的产率产生硝基衍生物。本方法论证明了反应速率的显着提高以及高的o-选择性，优异的产率，易于处理和后处理简单。

  DOI：

  10.2174/1570178612666150108000402
• 作为试剂：
  描述：

  3,4-二氢-2H-苯并[1,4]恶嗪-6-甲酸甲酯 、 2,6-dichloro-4-(2,3-dihydro-1,4-benzoxazin-4-ylcarbonyl)phenol 、 3,5-dichloro-4-hydroxybenzoyl chloride 以 3-硝基-4-羟基苯甲酸甲酯 、 乙酸乙酯 为溶剂， 生成 methyl 4-(3,5-dichloro-4-hydroxybenzoyl)-3,4-dihydro-2H-benzo[1,4]oxazine-6-carboxylate
  参考文献：
  名称：

  Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

  摘要：

  本发明提供了一种药物组合物，用于预防或治疗涉及尿酸的病理（高尿酸血症、痛风石、急性痛风性关节炎、慢性痛风性关节炎、痛风性肾脏、尿路结石、肾功能障碍、冠状动脉疾病、缺血性心脏病等），并且在时间稳定性和溶解性（分解性）方面具有优越性。 【解决手段】本发明的药物组合物是一种药物组合物，包括下式【1】所表示的含氮融合环化合物或其药学上可接受的盐，以及一种或多种药学上可接受的添加剂，其中所述的含氮融合环化合物或其药学上可接受的盐与碱性添加剂不接触： 其中每个符号如说明书中所述。

  公开号：

  US20080305169A1

文献信息

• 2-(甲硫基)苯并[d]噁唑-5-羧酸及其用途
  申请人：南通大学

  公开号：CN104086505B

  公开（公告）日：2016-05-04

  本发明公开了一种2-（甲硫基）苯并[d]噁唑-5-羧酸及其用途，产品有下列方法制得：？3-硝基-4-羟基苯甲酸甲酯的合成；3-氨基-4-羟基苯甲酸的合成；2-巯基苯并[d]噁唑-5-羧酸的合成；2-(甲硫基)苯并[d]噁唑-5-羧酸的合成；测试结果表明，在（-2～0）V的电位范围内，2-（甲硫基）苯并[d]噁唑-5-羧酸的电致化学发光性能很稳定，且在水相中的发光强度比在有机相中有明显的增强。
• Nitrogen-containing fused ring compounds and use thereof
  申请人：Hirata Kazuyuki

  公开号：US20070010670A1

  公开（公告）日：2007-01-11

  A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

  一种包含氮含有融合环化合物的URAT1活性抑制剂，其化学式如下所示[1]： 其中每个符号如描述中所定义。本发明对于预防或治疗显示尿酸参与的病理学，如高尿酸血症、痛风石、急性痛风性关节炎、慢性痛风性关节炎、痛风性肾脏、尿路结石、肾功能障碍、冠状动脉疾病、缺血性心脏病等方面具有用处。
• 4-(Pyrrolidinyl)methoxybenzoic Acid Derivatives as a Potent, Orally Active VLA-4 Antagonist
  作者：Jun Chiba、Shin Iimura、Yoshiyuki Yoneda、Yuichi Sugimoto、Takao Horiuchi、Fumito Muro、Yuichi Ochiai、Tomomi Ogasawara、Masao Tsubokawa、Yutaka Iigou、Gensuke Takayama、Tomoe Taira、Yoshimi Takata、Mika Yokoyama、Tohru Takashi、Atsushi Nakayama、Nobuo Machinaga

  DOI：10.1248/cpb.54.1515

  日期：——

  A novel series of benzoic acid derivatives as VLA-4 antagonists were synthesized. Optimization, focusing on activity and lipophilicity needed for cell permeability, resulted in the identification of 15b and 15e with good activity (IC50=1.6 nM each) and moderate lipophilicity (Log D=2.0, 1.8). Furthermore, 15e demonstrated efficacy in murine asthma model by an oral dose of 30 mg/kg.

  合成了一系列苯甲酸衍生物作为VLA-4拮抗剂。优化侧重于活性和细胞通透性所需的亲脂性，最终鉴定出活性良好（IC50分别为1.6纳摩尔）和适度亲脂性（Log D=2.0，1.8）的化合物15b和15e。此外，化合物15e在30毫克/千克口服剂量下对小鼠哮喘模型显示出疗效。
• ION-ACTIVATED PHOTOLABILE COMPOUNDS
  申请人：HOWARD HUGHES MEDICAL INSTITUTE

  公开号：US20180251441A1

  公开（公告）日：2018-09-06

  The presently-disclosed subject matter relates to analyte-activated photolabile compounds. The compounds include the formula: wherein Z includes a maskable molecule; L is selected from a bond, C, C(O), O, alkyl, (O)alkyl, and alkoxy; R 1 is selected from H, halogen, alkyl, and acyl; each R 2 is independently selected from H, alkyl, aryl, and acyl, and is optionally substituted with one or more heteroatoms independently selected from COOH and COO(alkyl); and R 3 is selected from H, alkyl, aryl, halogen, CN, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, CHO, COOH, COO(alkyl), COO(aryl), PO 3 H 2 , and SO 3 H, and is optionally substituted with one or more heteroatoms independently selected from N, O, and S, halogen, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, NO 2 , CHO, COO, COOH, COO(alkyl), COO(aryl), C(O)NR 2 , PO 3 H 2 , and/or SO 3 H. Also provided are methods of detecting calcium and treating a subject with the analyte-activated photolabile compounds.

  目前披露的主题事项涉及分析物激活的光敏化合物。这些化合物包括以下公式：其中Z包括可掩蔽的分子；L选自键、C、C(O)、O、烷基、(O)烷基和烷氧基；R1选自H、卤素、烷基和酰基；每个R2独立选自H、烷基、芳基和酰基，并且可以选择性地用独立选自COOH和COO(烷基)的一个或多个杂原子替换；R3选自H、烷基、芳基、卤素、CN、OH、O(烷基)、O(芳基)、SH、S(烷基)、S(芳基)、胺、CHO、COOH、COO(烷基)、COO(芳基)、PO3H2和SO3H，并且可以选择性地用独立选自N、O、S、卤素、OH、O(烷基)、O(芳基)、SH、S(烷基)、S(芳基)、胺、NO2、CHO、COO、COOH、COO(烷基)、COO(芳基)、C(O)NR2、PO3H2和/或SO3H的一个或多个杂原子替换。还提供了检测钙和处理主体与该分析物激活的光敏化合物的方法。
• [EN] ION-ACTIVATED PHOTOLABILE COMPOUNDS<br/>[FR] COMPOSÉS PHOTOLABILES ACTIVÉS PAR IONS
  申请人：HUGHES HOWARD MED INST

  公开号：WO2017040805A1

  公开（公告）日：2017-03-09

  The presently-disclosed subject matter relates to analyte-activated photolabile compounds. The compounds include the formula: wherein Z includes a maskable molecule; L is selected from a bond, C, C(O), O, alkyl, (O)alkyl, and alkoxy; R1 is selected from H, halogen, alkyl, and acyl; each R2 is independently selected from H, alkyl, aryl, and acyl, and is optionally substituted with one or more heteroatoms independently selected from COOH and COO(alkyl); and R3 is selected from H, alkyl, aryl, halogen, CN, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, CHO, COOH, COO(alkyl), COO(aryl), PO3H2, and SO3H, and is optionally substituted with one or more heteroatoms independently selected from N, O, and S, halogen, OH, O(alkyl), O(aryl), SH, S(alkyl), S(aryl), amine, NO2, CHO, COO, COOH, COO(alkyl), COO(aryl), C(O)NR2, PO3H2, and/or SO3H. Also provided are methods of detecting calcium and treating a subject with the analyte-activated photolabile compounds.

  目前披露的主题事项涉及分析物激活的光敏化合物。这些化合物包括以下公式：其中Z包括可屏蔽分子；L选自键、C、C(O)、O、烷基、(O)烷基和烷氧基；R1选自H、卤素、烷基和酰基；每个R2独立选自H、烷基、芳基和酰基，并且可以选择性地用独立选自COOH和COO(烷基)的一个或多个杂原子取代；R3选自H、烷基、芳基、卤素、CN、OH、O(烷基)、O(芳基)、SH、S(烷基)、S(芳基)、胺、CHO、COOH、COO(烷基)、COO(芳基)、PO3H2和SO3H，并且可以选择性地用独立选自N、O和S、卤素、OH、O(烷基)、O(芳基)、SH、S(烷基)、S(芳基)、胺、NO2、CHO、COO、COOH、COO(烷基)、COO(芳基)、C(O)NR2、PO3H2和/或SO3H的一个或多个杂原子取代。还提供了检测钙和用分析物激活的光敏化合物治疗主体的方法。

表征谱图